Keyword Analysis & Research: keynote 028 cervical

Keyword Analysis



Keyword Research: People who searched keynote 028 cervical also searched

Frequently Asked Questions

What is the keynote-158 study?

Purpose: KEYNOTE-158 (ClinicalTrials.gov identifier: NCT02628067) is a phase II basket study investigating the antitumor activity and safety of pembrolizumab in multiple cancer types. We present interim results from patients with previously treated advanced cervical cancer.

What is the keynote-028 trial?

Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1-positive, advanced solid tumor cohorts. Here, we present the results from the cohort of patients with advanced cervical cancer. …

How effective is pembrolizumab monotherapy for advanced cervical cancer?

Pembrolizumab monotherapy demonstrated durable antitumor activity and manageable safety in patients with advanced cervical cancer.

What is biobevacizumab for cervical cancer?

Bevacizumab is an antiangiogenic agent with efficacy in cervical cancer, representing a shift in the treatment paradigm.


Search Results related to keynote 028 cervical on Search Engine